FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
MB Number:	3235-0287				
stimated average burden					
ours per response	e 0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	ses)													
Name and Address CARTHY MARK	2. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RNN]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner							
	(First) IARMACEUTICA DY GROVE ROA	LS,	3. Date of Earliest Transaction (Month/Day/Year) 09/16/2015						title below)		er (specify belo	w)		
ROCKVII I E M	(Street) OCKVILLE, MD 20850			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting PersonForm filed by More than One Reporting Person				ne)
(City)	(State)	(Zip)		Т	able I	- Non-Deriv	ative Securit	es Acqu	ired, Di	sposed	of, or Bene	eficially Ow	ned	
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea			2A. Deemed Execution Date, if		Code (Instr.	(4	(A) or Disposed o				Securities Beneficially wing Reported		6. Ownership Form:	7. Nature of Indirect Beneficial Ownership
					Coo	de V A	mount (A) o	r Price				or Indirect (I) (Instr. 4)	(Instr. 4)	
							splays a cu		· u.i.u O.					
1. Title of Derivative Conversi Security (Instr. 3) Price of Derivativ Security	e (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transacti Code	5. Num of Derive Securi Acqui	mber ative ities	uired, Dispo	sed of, or Be nvertible securcisable and Date	7. Tit Amou Unde Secur	le and unt of crlying	d		9. Number of Derivative Securities Beneficially Owned	Ownersl Form of Derivati Security	Beneficia Ownershi
Derivative Conversion Security or Exerci (Instr. 3) Price of	Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transacti Code	5. Num of Derive Securi Acqui (A) or	mber ative ities ired seed of 3, 4,	uired, Dispo options, co 6. Date Exe Expiration	sed of, or Be nvertible securcisable and Date	7. Tit Amou Unde Secur	ele and unt of erlying rities	d	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially	Ownersl Form of Derivati Security Direct (I or Indire	of Indirect Beneficia Ownershi (Instr. 4)
Derivative Conversion or Exerci (Instr. 3) Price of Derivativ	Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transacti Code	5. Numion of Derivation Securial Acquiration (A) on Dispo (D) (Instr.	mber ative ities ired seed of 3, 4,	uired, Dispo options, co 6. Date Exe Expiration	sed of, or Be nvertible securcisable and Date //Year)	7. Tit Amou Unde Secur	ele and unt of rlying rities . 3 and 4	4) Limount r Jumber	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction	Ownersl Form of Derivati Security Direct (I or Indirects)	of Indirect Beneficia Ownershi (Instr. 4)

Reporting Owner Name / Address	Relationships					
reporting 6 wher reduces	Director	10% Owner	Officer	Other		
CARTHY MARK C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE, MD 20850	X					

Signatures

/s/ Tae Heum Jeong, as attorney-in-fact for Mark Carthy	09/18/2015
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.